Heart Disease Doesn't Sneak Up on People Who Are Paying Attention
Dr. Jeff Kindred, DOWe all know someone who had a heart attack or stroke and was described as perfectly healthy beforehand.
No symptoms. Active lifestyle. Looked fine. And then, seemingly out of nowhere, a major cardiovascular event.
I want to ask an honest question: were they really healthy? Or did nobody — including their physician — have the right information to see what was building?
Heart disease does not have to sneak up on people. It accumulates over years, it leaves measurable tracks, and the tools to detect it early exist. What is often missing is a physician with the time and the right testing to actually use them.
The Patient I See Most Often
He is in his late 40s or early 50s. He works hard, stays reasonably active, takes a handful of supplements. He has not seen a physician in a few years because, as he puts it, he does not have any issues. When his blood pressure reads 148 over 92 at the visit, he tells me that it is always elevated at the doctor — it is just white coat hypertension. He has not checked it at home. He takes fish oil because he heard it is good for his heart. He sees a chiropractor regularly.
He is not doing anything wrong. He is doing what a lot of men do — managing around a system that has not given him a compelling reason to engage with it.
But here is the clinical reality: persistently elevated blood pressure accelerates arterial damage whether the setting is a medical office or not. Unmonitored blood pressure is not managed blood pressure. Fish oil and chiropractic care, whatever their other merits, do not slow atherosclerosis. And “I feel fine” is not a cardiovascular risk assessment.
This is exactly the patient who is most at risk of becoming the person we all describe as having been perfectly healthy right up until he wasn’t.
What Your Standard Lipid Panel Is Actually Telling You
Most people who get annual bloodwork receive a standard lipid panel: total cholesterol, LDL, HDL, and triglycerides. LDL — the so-called bad cholesterol — gets the most attention. If it is below a certain threshold, most physicians move on.
The problem is that LDL measures the concentration of cholesterol carried inside LDL particles. It does not tell you how many particles are actually circulating in your blood. And it is the particles — not just the cholesterol inside them — that drive atherosclerosis.
Think of it this way. Imagine two people with identical LDL readings. One has a smaller number of large, buoyant LDL particles. The other has a larger number of small, dense particles. The cholesterol concentration looks the same on the lab report. But the second person has significantly more atherogenic particles working against their arteries. Standard LDL cannot distinguish between these two pictures.
This is called LDL discordance, and it is not rare. It is particularly common in people with metabolic syndrome, insulin resistance, elevated triglycerides, or low HDL — a profile that describes a very large portion of middle-aged adults in this country. [1]
What ApoB Actually Measures
Apolipoprotein B — ApoB — is a protein that sits on the surface of every atherogenic lipoprotein particle in your blood. Every LDL particle has exactly one ApoB molecule. So does every VLDL, IDL, and Lp(a) particle. This means that an ApoB measurement gives you a direct count of the total number of atherogenic particles circulating in your blood.
One number. Every relevant particle. No arithmetic required.
Multiple large studies have demonstrated that ApoB is a better predictor of cardiovascular events than LDL-C, particularly in populations where discordance between LDL and particle count is common. [1] The European Society of Cardiology now recommends ApoB as a primary treatment target. The American Heart Association considers it a useful marker, particularly for patients at higher risk or with metabolic abnormalities.
It is also inexpensive, widely available, and rarely ordered in standard primary care.
Knowing Your Number Is Not Enough Without a Plan
The other tool I use that most standard care does not include is coronary artery calcium scoring — a CAC score. This is a low-dose CT scan that directly measures calcified plaque in the coronary arteries. It is not a prediction model. It is a look at what is actually happening in your arteries right now. A CAC score of zero in a person over 40 carries a very low short-term cardiovascular risk. A high score changes the conversation entirely. [2]
I monitor my own.
I am an active person. I exercise consistently. I care deeply about longevity and take a holistic approach to my own health. By most outward measures I would be described as healthy. And I take a statin, ezetimibe, and blood pressure medication.
I mention this because patients regularly assume that someone with my approach — active, focused on prevention, interested in the full picture — would avoid pharmaceutical interventions in favor of lifestyle alone. That assumption has it backwards. I take these medications because I am focused on longevity. I have a strong family history of cardiovascular disease on both sides. The honest reality of cardiovascular medicine is that you cannot outrun your genetics, no matter how well you eat or how consistently you train. I keep my own ApoB around 60 mg/dL. I check my CAC score. I monitor my blood pressure at home, not just in a medical office.
Being holistically focused means using every evidence-based tool available — including medication when the evidence supports it. It does not mean avoiding medication because it feels less natural than a supplement. Needing medication does not mean you have failed. It means you are paying attention.
On Statins and the Stigma Around Taking Them
I see this regularly: a patient who clearly needs lipid management, who resists medication because they feel it means something has gone wrong, or because they have heard statins are dangerous, or because they would rather take a supplement that feels more natural.
I understand the instinct. I also want to be direct about the evidence.
Statins are among the most studied medications in the history of medicine. Major meta-analyses covering hundreds of thousands of patients across dozens of randomized trials have demonstrated their efficacy at reducing cardiovascular events and their safety in the vast majority of people who take them. [3] The JUPITER trial showed significant reduction in cardiovascular events even in people with normal LDL but elevated inflammatory markers. [4] No supplement on the market has a comparable evidence base. The peptides currently being sold in the wellness space have not completed a single randomized controlled trial in humans. Statins have completed hundreds.
Can statins cause side effects? Yes. Muscle aches are the most commonly reported. Serious adverse events are rare. For patients who are concerned, my approach is to start at the lowest effective dose — which captures roughly 85 percent of the lipid-lowering benefit while significantly reducing the likelihood of side effects. Most people tolerate this well, and if they do not, there are alternatives.
Not everyone needs to be on a statin. Age, risk profile, family history, ApoB, CAC score, and other factors all inform that decision. But the person who is going to benefit most from early intervention is not the one who has already had a cardiovascular event. That conversation should happen long before anything goes wrong — not in a cardiac rehabilitation unit.
The Levers We Actually Have
If your ApoB is elevated, these are the interventions with the strongest evidence behind them:
Statins are the most effective tool for lowering ApoB and LDL particle count. Starting at a low dose is a reasonable approach for most patients who are new to this class of medication.
Diet matters, specifically reducing saturated fat and increasing soluble fiber. Dietary changes alone have a modest but real effect on ApoB.
Weight loss improves the lipid profile meaningfully, particularly by reducing VLDL particles and triglycerides, which contribute to overall ApoB burden.
Exercise has a more modest direct effect on LDL and ApoB than most people expect, but its contribution to metabolic health, insulin sensitivity, and cardiovascular fitness makes it indispensable.
Ezetimibe and PCSK9 inhibitors are additional options for patients who cannot tolerate statins or need further reduction beyond what a statin alone achieves. PCSK9 inhibitors in particular can drive ApoB to very low levels and have strong cardiovascular outcome data.
The right combination depends on the individual. That is the conversation worth having with a physician who has the time to have it.
Why This Requires Someone Paying Attention
A standard annual physical with a basic lipid panel will not catch LDL discordance. It will not order an ApoB. It will not recommend a CAC score for a 48-year-old man with a family history and borderline metabolic markers. It will not follow up on a blood pressure reading that was attributed to white coat anxiety and then never checked again.
None of that is the fault of individual physicians. It is a consequence of a system where the appointment is fifteen minutes and the panel is two thousand patients and the incentive is to address the presenting complaint and move on.
Heart disease does not have to sneak up on anyone. But catching it early requires the right testing, a physician who knows your history and your family history, and enough time to actually look at the whole picture rather than just the numbers that fit on a standard form.
That is what I built this practice to do.
If you have not had an ApoB measured, if you do not know your CAC score, if you have been told your cholesterol is fine but you have risk factors that concern you — that is worth a conversation.
Set up a consultation with Dr. Kindred.
References
- Walldius G, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study). Lancet. 2001. PMID 11755609
- Detrano R, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008. PMID 18367736
- Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005. PMID 16214597
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008. PMID 18997196
Hi, Finch Health is a concierge medicine practice in Nashville, Tennessee. We practice evidence-based medicine — which means we look beyond the standard panel to find what actually matters for your long-term health.
Read more from the Hi, Finch Playbook:
Medicine 3.0 and Concierge Care: Why Your Relationship with Your Doctor Matters More Than Ever
Testosterone Replacement Therapy: Separating the Myths from the Evidence
GLP-1 Medications and Muscle Mass: What the Evidence Shows
Why We Use DEXA Scans in Concierge Medicine